12/16
08:27 am
thar
Tharimmune Announces Phase 2 Study Plan for TH104 in Patients With Moderate-to-Severe Pruritus Associated With Primary Biliary Cholangitis and Provides a Business Update [Yahoo! Finance]
Low
Report
Tharimmune Announces Phase 2 Study Plan for TH104 in Patients With Moderate-to-Severe Pruritus Associated With Primary Biliary Cholangitis and Provides a Business Update [Yahoo! Finance]
12/16
08:00 am
thar
Tharimmune Announces Phase 2 Study Plan for TH104 in Patients With Moderate-to-Severe Pruritus Associated With Primary Biliary Cholangitis and Provides a Business Update
Low
Report
Tharimmune Announces Phase 2 Study Plan for TH104 in Patients With Moderate-to-Severe Pruritus Associated With Primary Biliary Cholangitis and Provides a Business Update
12/10
07:32 am
thar
Tharimmune, Inc. (NASDAQ: THAR) was upgraded by analysts at RODMAN&RENSHAW to a "strong-buy" rating.
Medium
Report
Tharimmune, Inc. (NASDAQ: THAR) was upgraded by analysts at RODMAN&RENSHAW to a "strong-buy" rating.
12/6
04:35 pm
thar
Tharimmune Announces $2.02 Million Private Placement to Advance Development Programs [Yahoo! Finance]
High
Report
Tharimmune Announces $2.02 Million Private Placement to Advance Development Programs [Yahoo! Finance]
12/6
04:15 pm
thar
Tharimmune Announces $2.02 Million Private Placement to Advance Development Programs
Medium
Report
Tharimmune Announces $2.02 Million Private Placement to Advance Development Programs
12/6
02:49 pm
thar
Tharimmune, Inc. (NASDAQ: THAR) is now covered by analysts at Rodman & Renshaw. They set a "buy" rating and a $17.00 price target on the stock.
Low
Report
Tharimmune, Inc. (NASDAQ: THAR) is now covered by analysts at Rodman & Renshaw. They set a "buy" rating and a $17.00 price target on the stock.
11/18
08:22 am
thar
Tharimmune Presents Positive Clinical Data at AASLD the Liver Meeting(R) to Support TH104 for Chronic Pruritus in Chronic Liver Disease [Yahoo! Finance]
High
Report
Tharimmune Presents Positive Clinical Data at AASLD the Liver Meeting(R) to Support TH104 for Chronic Pruritus in Chronic Liver Disease [Yahoo! Finance]
11/18
08:00 am
thar
Tharimmune Presents Positive Clinical Data at AASLD the Liver Meeting(R) to Support TH104 for Chronic Pruritus in Chronic Liver Disease
Medium
Report
Tharimmune Presents Positive Clinical Data at AASLD the Liver Meeting(R) to Support TH104 for Chronic Pruritus in Chronic Liver Disease
11/13
08:00 am
thar
Tharimmune Granted European Patent for Delivery of Optimized Molecularly Targeted Therapeutics
High
Report
Tharimmune Granted European Patent for Delivery of Optimized Molecularly Targeted Therapeutics
11/4
09:00 am
thar
Tharimmune Announces Upcoming Conference Presentations
High
Report
Tharimmune Announces Upcoming Conference Presentations
10/30
08:00 am
thar
Tharimmune Receives Positive Regulatory Feedback From EMA for TH104 Clinical Program for Chronic Pruritus in Primary Biliary Cholangitis
High
Report
Tharimmune Receives Positive Regulatory Feedback From EMA for TH104 Clinical Program for Chronic Pruritus in Primary Biliary Cholangitis
10/28
09:00 am
thar
Tharimmune Presents Favorable TH104 Phase 1 Clinical Data at the American College of Gastroenterology 2024 Annual Scientific Meeting
Medium
Report
Tharimmune Presents Favorable TH104 Phase 1 Clinical Data at the American College of Gastroenterology 2024 Annual Scientific Meeting
10/25
08:00 am
thar
Tharimmune Announces Upcoming Conference Presentations
Medium
Report
Tharimmune Announces Upcoming Conference Presentations